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Identity 
Other names: AXIN; MGC52315 
HGNC (Hugo): AXIN1 
Location: 16p13.3 
Note 
According to Entrez gene and Ensembl the isoform a 
starts at 337440 and ends at 402464 bp with the total 
lenght of 65025 bp. The isoform b starts at 338122 and 
ends at 397025 with the total lenght of 58904 bp. Zeng 
et al. (1997) renamed the gene that was originally 
termed Fu to Axin in order to avoid confusion with the 
unrelated Drosophila gene fused. 
DNA/RNA 
Description 
Axin 1 consists of 11 exons (isoform a). Full gene 
transcript product length is 3675 bp. Isoform b lacks an 
in-frame exon in the 3' coding region and is shorter 
with sequence length of 3567 bp (Salahshor and 
Woodgett, 2005) (Figure 1). 
Transcription 
There are two transcript variants. Variant 1 (encoding 
for isoform a) represents the longer transcript (NM 
003502.3). Variant 2 (encoding for isoform b) is shorter 
compared to variant 1 (NM 181050.2). According to 
Ensembl there are six transcripts of AXIN1 of which 
first two are well known isoforms a and b and the 
remaining 4 are still in research. 
Protein 
Note 
Protein name: Axin 1, Axin, Axis inhibitor, Axis 
inhibitor protein 1. 
Description 
At least two isoforms of protein axin are expressed. 
Longer isoform has all eleven exons translated and 
consists of 862 aminoacids while shorter has 826 
aminoacids translated from ten exons. Axin 1 protein 
can be recognized primarily by two domains, the N-
terminal RGS domain (regulators of G-protein 
signaling) and the C-terminal DIX domain (dishevelled 
and axin) (Luo et al., 2005; Shibata et al., 2007). RGS 
domain is needed for APC binding while DIX domain 
for homodimerization and heterodimerization 
(Ehebauer and Arias, 2009; Noutsou et al., 2011). 
There is also a central region of the protein that binds 
GSK3beta and beta-catenin. Axin protein has nuclear 
localization (NLS) and nuclear export (NES) sequences 
as well. It is well known that axin is a scaffold protein 
that can shuttle between the cytoplasm and the nucleus. 
 
Figure 1. Genomic structure of Axin 1. Axin 1 is composed of 10 exons and they encode isoform a, while in isoform b exon 8 is spliced 
out. 
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Nucleo-cytoplasmatic shuttling under normal 
circumstances suggests existence of possible "salvage 
pathway" that would be activated by axin translocati n 
to the nucleus in order to reduce beta-catenin oncogenic 
activity by exporting nuclear beta-catenin and 
degrading it in the cytoplasm (Wiechens et al., 2004). 
Axin can also undergo posttranslational modifications. 
Phosphorilation by casein kinase 1 (CK1) enhances 
binding of GSK3beta and AXIN1. For activation of 
JNK pathway axin needs to be SUMOylated (Kim et 
al., 2008) (Figure 2). 
 
Figure 2. Two crystallized domains of the Axin 1 protein are 
shown: (A) RGS and (B) DIX. 
Expression 
Axin is expressed ubiquitously. 
Localisation 
Axin is predominantlly expressed in the cytoplasm, but 
periplasmic and nuclear localization are also observed 
depending on the stimulation of the cells (Cong and 
Varmus, 2004; Luo and Lin, 2004). In nonstimulated 
cells, axin colocalizes with Smad3. The subcellular 
location of axin is not well defined in the literature. It 
has been reported that physiological concentrations of 
axin is low in Xenopus egg cells. It has also been 
shown that it is located in cytoplasmic puncta in living 
mammalian cells. Wang et al. (2009) report that axin 1 
is highly co-localized with beta-catenin in the 
cytoplasm of human cumulus cells and that this 
localization denotes intact wnt signaling. Pecina-Sl us 
et al. (2011) showed the subcellular location of axin in 
normal brain white matter and glioblastoma tissue. The
majority of glioblastomas (69.04%) had axin localized 
in the cytoplasm. Nevertheless, 9.5% of glioblastomas 
samples had axin localized in the nucleus (Figure 3). 
Distribution of axin was reported previously by 
Anderson et al. (2002) in neoplastic colon. Altered 
nuclear expression of axin seen in colon polyps and
carcinomas may be a consequence of the loss of full-
length APC and the advent of nuclear beta-catenin. 
 
Figure 3. Glioblastoma samples immunohistochemically 
stained for protein expression of axin. (A) Cytoplasmic 
localization of axin and (B) nuclear localization of axin. 
Function 
Tumor suppressor protein Axin 1 is an inhibitor of the 
Wnt signaling pathway (Polakis, 2000; Salahshor and
Woodgett, 2005). As a scaffold protein, its main role is 
binding multiple members of Wnt signaling and 
formation of the beta-catenin destruction complex. It 
down-regulates beta-catenin, wnt pathway's main 
effector signaling molecule, by facilitating its 
phosphorylation by GSK3-beta (Hart et al., 1998). It 
binds directly to APC (adenomatous polyposis coli), 
beta-catenin, GSK3-beta and dishevelled forming a so 
called "beta-catenin destruction complex" in which 
phosphorylated beta-catenin is targeted for quick 
ubiquitinilation and degradation in the 26S proteosome 
(Yamamoto et al., 1999; Logan and Nusse, 2004). In 
response to wnt signaling, or under the circumstances 
of mutated axin or APC, beta-catenin is stabilized, 
accumulates in the cytoplasm and enters the nucleus, 
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where it finds a partner, a member of the DNA binding 
protein family LEF/TCF. Together they stimulate the 
expression of target genes including c-myc, c-jun, fra-1 
and cyclin D1. In developement Axin controls 
dorsoventral polarity axis formation (Zeng et al., 1997; 
Wodarz and Nusse, 1998) by two independent 
mechanisms: downregulation of beta-catenin, but also
by activation of Wnt-independent JNK signaling 
activation. Axin has a role in determining cell's fate 
upon damage, haematopoetic stem cells differentiation 
(Reya et al., 2003) and transforming growth factor beta 
signaling (Furuhashi et al., 2001). Reports indicate that 
beta-catenin and axin regulate critical developmental 
processes of normal CNS development (Pecina-Slaus, 
2010). 
Axin interacts with a number of proteins including: 
APC, Axam, Axin, beta-catenin, Ccd1, CKI, DAXX, 
DCAP, Diversin, Dvl, gamma-tubulin, GSK3beta, 
HIPK2, I-mfa, LRP5/LRP6, MDFIC, MEKK1, 
MEKK4, P53, PIAS, Pirh2, PP2A, Rnf11, Zbed3, 
Tip60, Smad3, Smad6, and Smad7 (Cliffe et al., 2003; 
Chen et al., 2009; Fumoto et al., 2009; Li et al., 2009; 
Choi et al., 2010; Kim and Jho, 2010). 
Homology 
Homologs are found in: Pan troglodytes, Canis lupus 
familiaris, Bos taurus, Mus musculus, Rattus 
norvegicus, Gallus gallus, Danio rerio. 
Mutations 
Note 
According to HGMD there are 3 missense mutations 
reported for AXIN 1 in colorectal carcinoma. Nikuseva 
Martic et al. (2010) identified gross deletions (Loss of 
Heterozygosity) of AXIN 1 in 6.3% of glioblastomas, 
in one neuroepithelial dysembrioplastic tumor and i 
one medulloblastoma. In a primary hepatocellular 
carcinoma 13 somatic events were reported by OMIM, 
a 33-bp deletion in exon 3 of the AXIN1 gene, and 12 
missense mutations. OMIM also reports on 





In a primary hepatocellular carcinoma (HCC), Satoh et 
al. (2000) found a 33-bp deletion in exon 3 of the 
AXIN1 gene, involving 2 glycogen synthase kinase-3-
beta phosphorylation sites. In addition to this deletion 
they found 12 missense mutations, of which 9 occurred 
in codons encoding serine or threonine residues. They 
confirmed that all 13 mutations found in primary HCCs 
occurred as somatic events. Taniguchi et al. (2002) 
found  
AXIN1 mutations in seven (9.6%) HCCs. The AXIN1 
mutations included seven missense mutations, a 1 bp
deletion, and a 12 bp insertion. Loss of heterozygosity 
at the AXIN1 locus was present in four of five 
informative HCCs with AXIN1 mutations, suggesting a 
tumor suppressor function of this gene. Park et al. 
(2005) showed that mutations of AXIN 1 are late 
events in hepatocellular carcinogenesis. 
Medulloblastoma 
Note 
To find out if Axin is also involved in the pathogenesis 
of sporadic medulloblastomas, Dahmen et al. (2001) 
analyzed 86 cases and 11 medulloblastoma cell lines
for mutations in the AXIN1 gene. Using single-strand 
conformation polymorphism analysis, screening for 
large deletions by reverse transcription-PCR, and 
sequencing analysis, a single somatic point mutation in 
exon 1 (Pro255Ser) and seven large deletions (12%) of 
AXIN1 were detected. Baeza et al. (2003) screened 39 
sporadic cerebellar medulloblastomas for alterations in 
the AXIN1 gene. The authors found missense AXIN1 
mutations in two tumours, CCC-->TCC at codon 255 
(exon 1, Pro-->Ser) and TCT-->TGT at codon 263 
(exon 1, Ser-->Cys). Furthermore, the A allele at the
G/A polymorphism at nucleotide 16 in intron 4 was 
significantly over-represented in medulloblastomas (39 
cases; G 0.76 vs-A 0.24) compared to healthy 
individuals (86 cases; G 0.91 vs A 0.09; P=0.0027). 
Yokota et al. (2002) showed another AXIN1 mutation 
in exon 3, corresponding to GSK-3beta binding site. 
Colorectal carcinoma 
Note 
Hart et al. (1998) report on overexpression of Axin1 i  
connection to the downregulation of wild-type beta-
catenin in colon cancer cells. In addition, Axin1 
dramatically facilitated the phosphorylation of APC 
and beta-catenin by GSK3 beta in vitro. Another group 
(Jin et al., 2003) analyzed 54 colorectal cancer tissues 
for mutations in AXIN1 gene. They found 3 silent 
mutations, 6 missense point mutations in different 
functionally important regions. The missense mutation 
rate was hence 11%, suggesting that Axin 1 deficiency 
may contribute to the onset of colorectal tumorigenesis. 
Segditsas and Tomlinson (2006) report on mutations in 
AXIN1 in microsatellite-unstable colon cancers. Three 
AXIN1 missense variants P312T, R398H, and L445M 
were detected in 1 of 124 patients with multiple 
colorectal adenomas. Three other missense mutations, 
D545E, G700S, and R891Q, were found. The overall 
frequency of the rare variants was significantly higher 
in the patients as compared with the controls 
(Fearnhead et al., 2004). 
Brain tumors 
Note 
A sample of 72 neuroepithelial brain tumors was 
investigated for AXIN-1 gene changes by Nikuseva 
Martic et al. (2010). Polymorphic marker for AXIN-1, 
showed loss of heterozygosity in 11.1% of tumors. 
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Down regulation of axin expression and up regulation 
of beta-catenin were detected. Axin was observed in 
the cytoplasm in 68.8% of samples, in 28.1% in both 
the cytoplasm and nucleus and 3.1% had no expression. 
Comparison of mean values of relative increase of axin
and beta-catenin showed that they were significantly 
reversely proportional (P=0.014) in a set of 
neuroepithelial brain tumors. Pecina-Slaus et al. (2011) 
also explored axin's existence at the subcellular level in 
glioblastomas and showed that the highest relative 
quantity of axin was measured when the protein was in 
the nucleus and the lowest relative quantity of axin 
when the protein was localized in the cytoplasm. 
Ovarian endometroid adenocarcinomas 
Note 
Wu et al. (2001) report on a nonsense mutation in one 
ovarian endometroid adenocarcinoma (OEA). They 
also found another missense AXIN1 sequence 
alteration in OEA-derived cell lines. 
Lung cancer 
Note 
In 105 lung SCC and adenocarcinoma tissue samples, 
the cytoplasmic expression of Axin was significantly 
lower than in normal lung tissues. Western blot 
analysis also demonstrated that the relative expression 
quantity of Axin was significantly reduced in lung 
cancer tissues compared with normal lung tissues. 
Nuclear expression of Axin was observed in 21 cases 
(20%) of lung cancers (Xu et al., 2011). 
Oesophageal squamous cell carcinoma 
Note 
Nakajima et al. (2003) found reduced expression of 
Axin1 in oesophageal squamous cell carcinoma. 
Several mutations have also been reported in 
oesophageal squamous cell carcinoma. 
Cervical cancer 
Note 
Su et al. (2003) examined AXIN1 in cervical cancer. 
Among the 30 tested cervical cancers mutation analysis 
of AXIN1 revealed that one specimen had a 
heterozygous mutation at codon 740. Six 
polymorphisms were also found. 
Immunohistochemistry showed no relationship between 
the protein expression patterns and mutation of AXIN1. 
Prostate cancer 
Note 
Yardy et al. (2009) reported on AXIN1 mutations in 
advanced prostate cancer. They found 7 mutations in 
prostate cancer cases and 4 polymorphisms in prostate 
cancer cell lines. 
Caudal duplication anomaly 
Note 
Hypermethylation of the AXIN1 promoter is associated  
with the caudal duplication anomalies. Oates et al. 
(2006) examined methylation at the promoter region of 
the AXIN1 gene in monozygotic twins. The promoter 
region of the AXIN1 gene was significantly more 
methylated in the twin with the caudal duplication than 
in the unaffected twin. 
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